All Pfizer articles – Page 3
-
-
BusinessUS court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
FeatureCovalent inhibitor drugs
Exceptions to a long-held rule against chemically bonding to biological targets are powering new cancer medicines, finds Andy Extance
-
NewsAlzheimer’s disease: have drug developers been on the wrong track?
Dementia drug developers urged to look beyond amyloid
-
BusinessLonza to buy capsule manufacturer in $5.5bn deal
Swiss pharma firm looks to strengthen its position as world’s biggest drug manufacturing subcontractor
-
Business£90m fine for Pfizer and Flynn Pharma over excessive drug pricing
Markets watchdog imposes record fine for breaches of competition law
-
BusinessPfizer pulls back on UK and Ireland facilities
€400 million manufacturing plant expansion cancelled and two facilities to close
-
BusinessFormer Valeant and Philidor executives arrested for fraud
Prosecutors allege the men masterminded a kickback scheme between Valeant and the speciality pharmacy
-
NewsPfizer launches new biosimilar drug in US
Autoimmune disease treatment becomes only the second biosimilar to be approved by the FDA
-
PodcastGabapentin
Louise Crane documents the rise and fall of Gabapentin – from ‘wonder drug’ to illicit substance in just 50 years
-
BusinessPfizer to sell Hospira Infusion Systems to ICU Medical
$1bn deal brings together medical device units, as Pfizer focuses on Hospira’s biosimilars and generics
-
BusinessPfizer scraps plans to split
Previously separated ‘innovative’ and ‘value’ business segments will remain autonomous under Pfizer umbrella
-
NewsPharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
BusinessPfizer gambles on $14bn Medivation deal
Cancer specialist likely just one target in hunt for marketed drugs to offset patent expiries
-
BusinessUS government sued over merger crackdown
Business groups challenge Obama’s steps to limit tax inversions
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
NewsUS drug giant will no longer supply lethal injection drugs
With Pfizer’s exit no US-approved pharma firm will sell its drugs to be used in executions